[SCHEDULE 13G/A] Avalo Therapeutics, Inc. Amended Passive Investment Disclosure
Avalo Therapeutics stake disclosed by Affinity Asset
Avalo Therapeutics, Inc. is reported to have 2,900,000 shares of its common stock beneficially owned through Affinity Healthcare Fund, LP, with investment decisions made by Affinity Asset Advisors, LLC and its managing member, Michael Cho.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Avalo Therapeutics, Inc. is reported to have 2,900,000 shares of its common stock beneficially owned through Affinity Healthcare Fund, LP, with investment decisions made by Affinity Asset Advisors, LLC and its managing member, Michael Cho. As of June 30, 2026, these reporting persons held approximately 5.5% of Avalo’s outstanding common stock, based on 52,900,692 shares outstanding. They report sole voting and dispositive power over all 2,900,000 shares and no shared voting or dispositive power.
Key Figures
Shares beneficially owned:2,900,000 sharesOwnership percentage:5.5%Shares outstanding:52,900,692 shares+3 more
6 metrics
Shares beneficially owned2,900,000 sharesCommon stock of Avalo Therapeutics beneficially owned as of June 30, 2026
Ownership percentage5.5%Portion of Avalo Therapeutics common stock class beneficially owned as of June 30, 2026
Shares outstanding52,900,692 sharesAvalo Therapeutics common stock outstanding as of June 30, 2026
Sole voting power2,900,000 sharesShares over which reporting persons have sole power to vote
Sole dispositive power2,900,000 sharesShares over which reporting persons have sole power to dispose
Beneficial ownership dateJune 30, 2026Date as of which ownership and percentages are calculated
Key Terms
beneficially own, sole voting power, sole dispositive power, percent of class, +1 more
5 terms
beneficially ownfinancial
"the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 2,900,000 shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole voting powerfinancial
"the Reporting Persons have sole power to vote or to direct the vote of 2,900,000 shares"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"the Reporting Persons have sole power to dispose or to direct the disposition of 2,900,000 shares"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of classfinancial
"As of June 30, 2026, the Reporting Persons beneficially own approximately 5.5% of the Common Stock outstanding"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
investment managerfinancial
"Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Avalo Therapeutics (AVTX) do Affinity Asset Advisors and Michael Cho report?
Affinity Asset Advisors and Michael Cho report beneficial ownership of 2,900,000 shares of Avalo Therapeutics common stock, representing approximately 5.5% of the company’s outstanding common stock as of June 30, 2026.
How many Avalo Therapeutics (AVTX) shares are outstanding according to this filing?
The filing states that Avalo Therapeutics had 52,900,692 shares of common stock outstanding as of June 30, 2026, based on the company’s Form 10-Q filed on August 6, 2026.
Who directly holds the Avalo Therapeutics (AVTX) shares reported by Affinity Asset Advisors?
The 2,900,000 shares of Avalo Therapeutics common stock are directly held by Affinity Healthcare Fund, LP. Affinity Asset Advisors, LLC acts as investment manager and may be deemed to beneficially own these shares, along with Michael Cho.
What voting power do the reporting persons have over Avalo Therapeutics (AVTX) shares?
As of June 30, 2026, the reporting persons have sole voting power over 2,900,000 shares of Avalo Therapeutics common stock and no shared voting power over any shares.
What dispositive power is reported over Avalo Therapeutics (AVTX) shares?
The reporting persons state they have sole dispositive power over 2,900,000 shares of Avalo Therapeutics common stock and no shared dispositive power as of June 30, 2026.
Who are the reporting persons in this Avalo Therapeutics (AVTX) Schedule 13G/A?
The reporting persons are Affinity Asset Advisors, LLC, a Delaware limited liability company, and Michael Cho, its managing member and a citizen of the United States, each deemed to beneficially own the reported shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Avalo Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
05338F306
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
05338F306
1
Names of Reporting Persons
Affinity Asset Advisors, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,900,000.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,900,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,900,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
05338F306
1
Names of Reporting Persons
Michael Cho
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,900,000.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,900,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,900,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
IN, HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Avalo Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania, 19087
Item 2.
(a)
Name of person filing:
Affinity Asset Advisors, LLC
Michael Cho
(b)
Address or principal business office or, if none, residence:
450 Park Avenue
Suite 1403
New York, NY 10022
(c)
Citizenship:
Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
05338F306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held directly by the Fund.
As of June 30, 2026, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 2,900,000 shares of common stock, $0.001 par value per share ("Common Stock"), of Avalo Therapeutics, Inc. (the "Issuer").
(b)
Percent of class:
As of June 30, 2026, the Reporting Persons beneficially own approximately 5.5% of the Common Stock outstanding.
The percentages disclosed above are based on 52,900,692 shares of Common Stock of the Issuer outstanding as of June 30, 2026, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
As of June 30, 2026, the Reporting Persons have sole power to vote or to direct the vote of 2,900,000 shares of Common Stock.
(ii) Shared power to vote or to direct the vote:
As of June 30, 2026, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock.
(iii) Sole power to dispose or to direct the disposition of:
As of June 30, 2026, the Reporting Persons have sole power to dispose or to direct the disposition of 2,900,000 shares of Common Stock.
(iv) Shared power to dispose or to direct the disposition of:
As of June 30, 2026, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Affinity Asset Advisors, LLC
Signature:
/s/ Andrew Weinstein
Name/Title:
Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
